Screener
Inhibrx Biosciences, Inc. INBX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Interest income | 1,007 | 2,329 |
| Other income (expense), net | (12) | (50) |
| Total other expense | (2,514) | (410) |
| Loss before income tax expense | (33,441) | (43,311) |
| Provision for income taxes | — | — |
| Net loss | $(33,441) | $(43,311) |
| Net loss per share, basic and diluted | $(2.15) | $(2.80) |
| Shares used in computing net loss per share, basic and diluted | 15,585 | 15,468 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s EPS (diluted)?
- Inhibrx Biosciences, Inc. (INBX) reported EPS (diluted) of -$2.15 in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s EPS (diluted) changed year-over-year?
- Inhibrx Biosciences, Inc.'s EPS (diluted) increased by 23.2% year-over-year, from -$2.80 to -$2.15.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s EPS (diluted) has grown at a -33.6% compound annual growth rate (CAGR), from -$20.48 to -$9.04.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Inhibrx Biosciences, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude